All
All

What are you looking for?

All
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Quantitative analysis of p16 gene as a potential prognostic marker of bladder transitional cell carcinomas

Project goals

Bladder cancer is the second most frequent malignancy among the tumours of the urinary tract in men - prostate carcinoma being the first. Extensive heterogeneity in tumour behaviour and the absence of accurate method for the early detection of tumour progression or relapse lead to the intensive search for new prognostic markers. The aim of the proposed project is to verify the possible use of p16 gene as a prognostic marker for the follow-up of patients with bladder transitional cell carcinomas. We willestablish very sensitive and exact approach: real-time quantitative polymerase chain reaction (RQ-PCR). We will compare p16 status (normal, hemizygous deletion, homozygous deletion) in a normal patient's tissue, tumour and urine specimen. We will trto define the relationship between this potential marker and histopathological and clinical features of the tumour as well as continuous tumour progression and/or relapse in the cohort of patients. Moreover, we will test DNA from the urine sediment as a

Keywords

Public support

  • Provider

    Czech Science Foundation

  • Programme

    Post-graduate (doctorate) grants

  • Call for proposals

    Postdoktorandské granty 2 (SGA02002GA-PD)

  • Main participants

    Univerzita Karlova / 2. lékařská fakulta

  • Contest type

    VS - Public tender

  • Contract ID

Alternative language

  • Project name in Czech

    Kvantitativnˇ stanovenˇ genu p16 jako mo§n?ho prognostick?ho markeru u uroteli lnˇch n dor? moźov?ho mŘchěýe

  • Annotation in Czech

    N dory moźov?ho mŘchěýe jsou po karcinomu prostaty druhěm nejźastŘjçˇm urologickěm novotvarem u mu§?. Znaźn  heterogenita v chov nˇ n dor? a absence spolehliv? metody pro vźasnou detekci n dorov? progrese źi recidivy vedou k intensivnˇmu hled nˇ nověch prognostickěch znak?. Cˇlem navrhovan?ho projektu je ovŘýit mo§nost vyu§itˇ n dorov?ho supresorov?ho genu p16 jako prognostick?ho markeru pýi sledov nˇ pacient? s uroteli lnˇmi n dory moźov?ho mŘchěýe. Bude zavedena kvantitativnˇ polymerasov  ýetŘzov  reakce v re ln?m źase (RQ-PCR), velice citliv  a pýesn  metoda pro kvantifikaci gen?. Status genu p16 (norm lnˇ stav, hemizygotnˇ nebo homozygotnˇ delece) bude porovn v n mezi norm lnˇ tk nˇ, n dorovou tk nˇ a vzorkem moźi konkr?tnˇho pacienta. D?le§itousouź stˇ projektu bude definov nˇ vztah? tohoto mo§n?ho markeru jak k histopatologickěm a klinickěm parametr?m tumoru, tak i k dalçˇ progresi źi recidivŘ n doru sledovaněch pacient?. D le budeme testovat DNA moźov?ho sedimentu jako mo§ně zdroj informacˇ

Scientific branches

  • R&D category

  • CEP classification - main branch

    FD - Oncology and haematology

  • CEP - secondary branch

    EB - Genetics and molecular biology

  • CEP - another secondary branch

  • 10603 - Genetics and heredity (medical genetics to be 3)
    10604 - Reproductive biology (medical aspects to be 3)
    10605 - Developmental biology
    10608 - Biochemistry and molecular biology
    10609 - Biochemical research methods
    30101 - Human genetics
    30204 - Oncology
    30205 - Hematology

Completed project evaluation

  • Provider evaluation

    N - Nesplněno zadání

  • Project results evaluation

    Projekt byl pýedźasnŘ ukonźen na § dost ýeçitelky, vzhledem k n stupu na mateýskou dovolenou. Cˇlem projektu bylo vyu§ˇt alelickěch forem genu p 16 pro diagnostiku n dor? moźov?ho mŘchěýe. Jediněm pýˇnosem projektu bylo shrom §dŘnˇ klinick?ho materi lu p

Solution timeline

  • Realization period - beginning

    Jan 1, 2001

  • Realization period - end

    Jan 1, 2004

  • Project status

    S - Stopped (prematurely terminated) multi-year project

  • Latest support payment

Data delivery to CEP

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

  • Data delivery code

    CEP/2003/GA0/GA03GP/U/N/7:4

  • Data delivery date

    Jun 15, 2009

Finance

  • Total approved costs

    333 thou. CZK

  • Public financial support

    333 thou. CZK

  • Other public sources

    0 thou. CZK

  • Non public and foreign sources

    0 thou. CZK

Recognised costs

333 CZK thou.

Public support

333 CZK thou.

0%


Provider

Czech Science Foundation

CEP

FD - Oncology and haematology

Solution period

01. 01. 2001 - 01. 01. 2004